"10.1371_journal.pone.0140909","plos one","2015-11-11T00:00:00Z","Faseeha Noordeen; Catherine A Scougall; Arend Grosse; Qiao Qiao; Behzad B Ajilian; Georget Reaiche-Miller; John Finnie; Melanie Werner; Ruth Broering; Joerg F Schlaak; Andrew Vaillant; Allison R Jilbert","Department of Molecular and Cellular Biology, School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia; Department of Microbiology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka; SA Pathology, Hanson Institute, Centre For Neurological Diseases, Adelaide, SA, Australia; Department of Gastroenterology and Hepatology, University Hospital, University of Duisburg-Essen, Essen, Germany; Replicor Inc., Montreal, Quebec, Canada","Conceived and designed the experiments: FN RB AV ARJ. Performed the experiments: FN CAS AG QQ BBA GR-M MW. Analyzed the data: FN CAS QQ GR-M JF RB JFS AV ARJ. Wrote the paper: FN CAS AV ARJ.","This study was funded by Replicor Inc. Dr. Andrew Vaillant is employed by Replicor Inc. NAPs are protected by patents wholly owned by Replicor Inc and are currently in development for the treatment of hepatitis B / hepatitis D infection. Relevant patents are: US 8,067,385 Antiviral oligonucleotides targeting HBV US 8,008,270 Antiviral oligonucleotides targeting viral families US 7,358,068 Antiviral oligonucleotides, US 8,008,269 Antiviral oligonucleotides. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","11","Faseeha Noordeen","FN",12,TRUE,4,7,9,4,TRUE,TRUE,FALSE,0,NA,FALSE
